Evolocumab safely drops LDL cholesterol well below statin-only baseline, study suggests

The monoclonal antibody evolocumab produced highly significant reductions in low-density lipoprotein cholesterol, the "bad cholesterol," as an add-on to statins in all treatment groups, according to new data.